Botanix Quarterly Activities Report and Appendix 4C Q4 FY26
Filed with ASX · · 10 pages · English
Summary by 6ix AI
The report highlights a substantial increase in total prescriptions shipped and net revenue from its product Sofdra, alongside a notable improvement in operating cash outflow. Additionally, the company announced the appointment of a new Chief Operating Officer to strengthen its leadership team and drive strategic initiatives. The filing also includes details on corporate actions, including the issuance of shares and performance rights, as well as a compliance statement confirming adherence to accounting standards.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Botanix Pharmaceuticals' latest callBotanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call · Replay · Mar 2Read the transcript of Botanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings CallBotanix Pharmaceuticals Limited on 6ix
In the deck
Story so far
Earlier from Botanix Pharmaceuticals
- Notice of Allowance for US patent on Sofdra drug substance
- Intention to Grant a European patent on Sofdra applicator
- Botanix Quarterly Activities Report and Appendix 4C Q3 FY26
- Botanix reaches term sheet agreement with 2nd API supplier
- Successful renegotiation of API supply agreement
Later from Botanix Pharmaceuticals
- Appendix 4E & Annual Report for the Year Ended 30 June 2026
- S&P DJI Announces September 2026 Quarterly Rebalance
- Botanix Quarterly Activities Report and Appendix 4C Q1 FY27
Follow Botanix Pharmaceuticals into a list and get an email when it puts out news.
Follow Botanix Pharmaceuticals